Related Experiment Videos
Unresolved issues in the genesis and management of multiple endocrine neoplasia type 2
1Section of Endocrinology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Abstract:
It has been slightly less than 3 years since mutations of the RET proto-oncogene were identified in multiple endocrine neoplasia type 2. The period since the initial report has been one of intense activity with a wide spectrum of mutations identified in exons 10, 11, 13, 14, 15 and 16 of this gene. Recent studies have provided experimental evidence for an activating effect of the exon 11 and 16 mutations. Two questions are addressed in this report: the high rate of false positive tests in prospective screening studies and the implications for future interpretation of this test: and the mechanism of transformation in MEN 2.
Insights
RET proto-oncogene mutations are linked to multiple endocrine neoplasia type 2 (MEN 2). This report examines mutation screening, false positive rates, and the transformation mechanisms driving MEN 2.
Area of Science:
- Oncogenes and Cancer Genetics
- Endocrinology and Metabolism
Background:
- Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disorder.
- RET proto-oncogene mutations are key drivers of MEN 2 pathogenesis.
- Significant research has focused on RET mutations since their discovery.
Purpose of the Study:
- To analyze the spectrum of RET proto-oncogene mutations in MEN 2.
- To evaluate the high false positive rate in prospective screening studies.
- To elucidate the molecular mechanisms of transformation in MEN 2.
Main Methods:
- Review of recent studies on RET proto-oncogene mutations.
- Analysis of experimental evidence for mutation-activating effects.
- Assessment of prospective screening data for false positive rates.
Main Results:
- A wide spectrum of RET mutations identified in exons 10, 11, 13, 14, 15, and 16.
- Experimental evidence confirms activating effects for exon 11 and 16 mutations.
- High false positive rates observed in prospective screening studies.
Conclusions:
- RET proto-oncogene mutations are critical in MEN 2 development.
- Understanding mutation-activating effects is crucial for diagnosis.
- Further investigation is needed to refine screening protocols and understand MEN 2 transformation.